Evidence map›Paper›PMID 32090272›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2020

Immune and Inflammatory Determinants Underlying Alzheimer's Disease Pathology.

Janet E Baulch, Munjal M Acharya, Sudhanshu Agrawal, Lauren A Apodaca, Clarice Monteiro, Anshu Agrawal

Open access · greenAbstract read
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Unmasking a Paradox: Roles of the PD-1/PD-L1 Axis in Alzheimer's Disease-Associated Neuroinflammation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Review
  7. Article
  8. Innate and adaptive immunity in neurodegenerative disease.Cellular and molecular life sciences : CMLS · 2025
    Review
  9. CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study.Therapeutic advances in neurological disorders · 2025
    Article
  10. Review
  11. Effect ofInternational journal of molecular sciences · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Janet E BaulchDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, 92697, USA.
Munjal M AcharyaDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, 92697, USA.
Sudhanshu AgrawalDivision of Basic and Clinical Immunology, Department of Medicine, University of California, Irvine, Irvine, CA, 92697, USA.
Lauren A ApodacaDepartment of Radiation Oncology, University of California, Irvine, Irvine, CA, 92697, USA.
Clarice MonteiroDivision of Basic and Clinical Immunology, Department of Medicine, University of California, Irvine, Irvine, CA, 92697, USA.
Anshu AgrawalDivision of Basic and Clinical Immunology, Department of Medicine, University of California, Irvine, Irvine, CA, 92697, USA. aagrawal@uci.edu.ORCID 0000-0002-3323-9152
University of California, Irvine · US

Funding

UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 2000 to 2019
$37.0M
Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
Impaired ability of aged human dendritic cells to maintain mucosal toleranceR01AG045216 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGRAWAL, ANSHU · 2014 to 2018
$1.6M
Peripheral Immune mechanisms involved in the etiology of Alzheimer's diseaseR56AG064709 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGRAWAL, ANSHU · 2019 to 2019
$385k
California Institute for Regenerative Medicine DISC1-10079NCATS NIH HHS KL2 TR001416NIA NIH HHS AG045216NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG16573.NIA NIH HHS R01 AG045216NIA NIH HHS R56 AG064709
6 · The paper itself

Abstract

This study examines the link between peripheral immune changes in perpetuation of the Alzheimer's disease (AD) neuropathology and cognitive deficits. Our research design using human AD patients and rodent model is supported by past evidence from genomic studies. We observed an active immune response against Aβ as indicated by the increased Aβ specific IgG antibody in the serum of AD and patients with mild cognitive impairments as compared to healthy controls. A similar increase in IgG and decrease in IgM antibody against Aβ was also confirmed in the 5xFAD mouse model of AD. More importantly, we observed a negative correlation between reduced IgM levels and cognitive dysfunction that manifested as impaired memory consolidation. Strong peripheral immune activation was supported by increased activation of microglia in the brain and macrophages in the spleen of AD mice compared to wild type control littermates. Furthermore, inflammatory cytokine IL-21 that is involved in antibody class switching was elevated in the plasma of AD patients and correlated positively with the IgG antibody levels. Concurrently, an increase in IL-21 and IL-17 was observed in spleen cells from AD mice. Further investigation revealed that proportions of T follicular helper (Tfh) cells that secrete IL-21 are increased in the spleen of AD mice. In contrast to Tfh, the frequency of B1 cells that produce IgM antibodies was reduced in AD mice. Altogether, these data indicate that in AD the immune tolerance to Aβ is compromised leading to chronic immune/inflammatory responses against Aβ that are detrimental and cause neuropathology. Graphical Abstract Healthy subjects are tolerant to Aβ and usually react weakly to it resulting the in the production of IgM class of antibodies that are efficient at clearing up self-antigens such as Aβ without causing inflammation. In contrast, Alzheimer's disease patients mount a strong immune response against Aβ probably in an effort to clear up excessive Aβ. There is enhanced production of inflammatory cytokines such as IL-21 as well as an increase in Tfh cells that cause antibody class switching form IgM to IgG. The strong immune response is inefficient at clearing up Aβ and instead exacerbates inflammation that causes AD neuropathology and cognitive dysfunction.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAnimalsCognitive DysfunctionFemaleHumansImmunityInflammation MediatorsMaleMiceMice, TransgenicPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-42)Inflammation MediatorsPeptide FragmentsAlzheimer’s diseaseAβCognitionIL-21InflammationTfh

Identifiers

PMID32090272
PMCPMC7483328
OpenAlexW3007343519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.